義合控股(01662.HK)旗下生物醫學研發企業獲增資6000萬元
格隆匯10月12日丨義合控股(01662.HK)公佈,於2021年9月2日,華大海洋(公司的間接非全資附屬公司)、江蘇吉貝爾及目標公司(在資本投資前由華大海洋全資擁有的公司間接附屬公司)訂立資本投資及合作協議,據此江蘇吉貝爾有條件同意向目標公司出資人民幣6000萬元,其中約人民幣1290萬元已繳付及出資作為目標公司的註冊資本(佔資本投資後目標公司全部註冊資本的約30.0%)及約人民幣4710萬元已注入及入賬作為目標公司的資本儲備。
據悉,目標公司深圳華泓海洋生物醫藥有限公司在資本投資前為由華大海洋全資擁有的公司間接附屬公司,主要從事生物醫學技術研發。根據資本投資及合作協議,目標公司只可將江蘇吉貝爾的出資應用於海洋藥物的研發及其日常業務營運過程。
作為繼續探索與世界各地市場潛在實體進行戰略合作以獲得更大的海洋生物製藥市場份額的部分策略,是次與江蘇吉貝爾的合作將幫助華大海洋加快研發用於治療腫瘤及癌症等人類主要疾病的海洋藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.